177 related articles for article (PubMed ID: 9114724)
21. Contiguous four-guanosine sequence in c-myc antisense phosphorothioate oligonucleotides inhibits cell growth on human lung cancer cells: possible involvement of cell adhesion inhibition.
Saijo Y; Uchiyama B; Abe T; Satoh K; Nukiwa T
Jpn J Cancer Res; 1997 Jan; 88(1):26-33. PubMed ID: 9045892
[TBL] [Abstract][Full Text] [Related]
22. Antisense, RNAi, and gene silencing strategies for therapy: mission possible or impossible?
Rayburn ER; Zhang R
Drug Discov Today; 2008 Jun; 13(11-12):513-21. PubMed ID: 18549978
[TBL] [Abstract][Full Text] [Related]
23. Antisense oligonucleotides as inhibitors of genes that regulate AP-1: pharmacology and clinical development.
Dean NM; McKay RA; Holmlund J
Antisense Nucleic Acid Drug Dev; 1998 Apr; 8(2):147-51. PubMed ID: 9593055
[No Abstract] [Full Text] [Related]
24. Antisense therapy in oncology: new hope for an old idea?
Tamm I; Dörken B; Hartmann G
Lancet; 2001 Aug; 358(9280):489-97. PubMed ID: 11513935
[TBL] [Abstract][Full Text] [Related]
25. [Inhibitory effects of c-myc antisense oligonucleotide on estrogen-stimulating growth in human breast cancer cells: preliminary report].
Ueo H; Murakami A; Inoue H; Honda M; Nakashima H; Makino K; Akiyoshi T
Nihon Geka Gakkai Zasshi; 1994 Mar; 95(3):204. PubMed ID: 8177203
[No Abstract] [Full Text] [Related]
26. Downregulation of c-myc expression by antisense oligonucleotides inhibits proliferation of human smooth muscle cells.
Shi Y; Hutchinson HG; Hall DJ; Zalewski A
Circulation; 1993 Sep; 88(3):1190-5. PubMed ID: 8353880
[TBL] [Abstract][Full Text] [Related]
27. Antisense inhibition of N-myc reduces cell growth but does not affect c-myc expression in the neuroepithelioma cell line CHP100.
Rosolen A; Whitesell L; Ikegaki N; Kennett R; Neckers LM
Prog Clin Biol Res; 1991; 366():29-36. PubMed ID: 2068146
[No Abstract] [Full Text] [Related]
28. Oligonucleotides--from design to the clinic.
Bennett CF
Curr Opin Mol Ther; 1999 Jun; 1(3):296. PubMed ID: 11713793
[No Abstract] [Full Text] [Related]
29. Inhibitory effects of antisense oligodeoxynucleotides targeting c-myc mRNA on smooth muscle cell proliferation and migration.
Biro S; Fu YM; Yu ZX; Epstein SE
Proc Natl Acad Sci U S A; 1993 Jan; 90(2):654-8. PubMed ID: 8421701
[TBL] [Abstract][Full Text] [Related]
30. Locked nucleic acid: a potent nucleic acid analog in therapeutics and biotechnology.
Jepsen JS; Sørensen MD; Wengel J
Oligonucleotides; 2004; 14(2):130-46. PubMed ID: 15294076
[TBL] [Abstract][Full Text] [Related]
31. Pharmacological inactivation of MYC for the treatment of cancer.
Felsher DW; Bradon N
Drug News Perspect; 2003; 16(6):370-4. PubMed ID: 12973448
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of c-myc expression by phosphorothioate antisense oligonucleotide identifies a critical role for c-myc in the growth of human breast cancer.
Watson PH; Pon RT; Shiu RP
Cancer Res; 1991 Aug; 51(15):3996-4000. PubMed ID: 1855215
[TBL] [Abstract][Full Text] [Related]
33. Antisense of oligonucleotides and the inhibition of oncogene expression.
Prins J; de Vries EG; Mulder NH
Clin Oncol (R Coll Radiol); 1993; 5(4):245-52. PubMed ID: 8398922
[TBL] [Abstract][Full Text] [Related]
34. Effect of phosphorothioated oligonucleotides on neointima formation in the rat carotid artery. Dissecting the mechanism of action.
Bennett MR; Lindner V; DeBlois D; Reidy MA; Schwartz SM
Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):2326-32. PubMed ID: 9409198
[TBL] [Abstract][Full Text] [Related]
35. Antitumor effects of antisense phosphorothioate c-myc oligodeoxynucleotides: a question of mechanism.
Stein CA
J Natl Cancer Inst; 1996 Apr; 88(7):391-3. PubMed ID: 8618230
[No Abstract] [Full Text] [Related]
36. Antisense oligonucleotides as a tool for gene functionalization and target validation.
Bennett CF; Cowsert LM
Biochim Biophys Acta; 1999 Dec; 1489(1):19-30. PubMed ID: 10806994
[No Abstract] [Full Text] [Related]
37. Enhancement of sensitivity of urinary bladder tumor cells to cisplatin by c-myc antisense oligonucleotide.
Mizutani Y; Fukumoto M; Bonavida B; Yoshida O
Cancer; 1994 Nov; 74(9):2546-54. PubMed ID: 7923012
[TBL] [Abstract][Full Text] [Related]
38. Nucleic acid therapeutics: state of the art and future prospects.
Gewirtz AM; Sokol DL; Ratajczak MZ
Blood; 1998 Aug; 92(3):712-36. PubMed ID: 9680338
[No Abstract] [Full Text] [Related]
39. Oligonucleotide therapeutics: clothing the emperor.
Gewirtz AM
Curr Opin Mol Ther; 1999 Jun; 1(3):297-306. PubMed ID: 11713794
[TBL] [Abstract][Full Text] [Related]
40. Antisense inhibition and adeno-associated viral vector delivery for reducing hypertension.
Phillips MI
Hypertension; 1997 Jan; 29(1 Pt 2):177-87. PubMed ID: 9039099
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
